Death Receptor 3: A Paradoxical Biomarker and Therapeutic Target in Pan-Cancer [0.03%]
死亡受体3：一个颇具争议的泛癌症生物标志物和治疗靶点
Wenxuan Fang,Junfang Du,Zedong Xu et al.
Wenxuan Fang et al.
Death receptor 3 (DR3/TNFRSF25) is a member of the tumor necrosis factor receptor superfamily, exhibiting dual roles in regulating tumor apoptosis and metastasis. Through literature review and pan-cancer analysis, this study reveals that DR...
FASN at the Crossroads of Tumor Metabolism, Immune Evasion, and Therapy Resistance: Mechanistic Insights and Therapeutic Opportunities [0.03%]
脂肪酸合成酶位于肿瘤代谢、免疫逃逸和治疗抵抗的十字路口：机制见解和治疗机会
Xuefeng Jiang,Guotao Fang,Wen Li et al.
Xuefeng Jiang et al.
Fatty acid synthase (FASN), the key enzyme driving de novo lipogenesis, has emerged as a central metabolic hub in cancer, linking aberrant lipid synthesis to tumor progression, immune escape, and therapy resistance. This review provides a c...
Multifaceted mechanisms and precision strategies to overcome therapeutic resistance in gallbladder cancer [0.03%]
克服胆囊癌治疗抵抗的多因素机制和精准策略
Qingliang Jiang,Gang Li,Hengyu Li et al.
Qingliang Jiang et al.
Gallbladder cancer (GBC) is a rare but highly aggressive malignancy with poor prognosis, largely due to the pervasive challenge of therapeutic resistance. Conventional chemotherapy, targeted therapy, and immunotherapy have shown limited eff...
Management of adverse events associated with TROP2-targeted antibody-drug conjugates in cancer patients [0.03%]
癌症患者靶向TROP2抗体药物偶联物相关不良事件的管理
Zuer He,Zijia Luo,Peilin Dai et al.
Zuer He et al.
Antibody-drug conjugates (ADCs) constitute an innovative category of anti-tumor therapeutics that selectively deliver cytotoxins to tumor cells, improving efficacy and reducing toxicity in comparison to systemic therapy. TROP2 serves as a s...
NRG1 fusions：the potential targeted treatment in non-small cell lung cancer(NSCLC) [0.03%]
NRG1融合基因：非小细胞肺癌(NSCLC)的潜在靶向治疗
Jiantao Zhang,Xiaonu Peng,Haibo Huang et al.
Jiantao Zhang et al.
Neuregulin 1 (NRG1) gene fusions represent a rare but clinically actionable oncogenic driver in non-small cell lung cancer (NSCLC). This review synthesizes recent advances in targeted therapies for NRG1 fusion-positive NSCLC, with a focus o...
TRAIL-Functionalized Nanoparticles in Cancer Therapy: Molecular Mechanisms and Translational Opportunities [0.03%]
肿瘤治疗中TRAIL功能化纳米粒子的作用机制及转化机遇
Dasari Sahithi,Urushi Rehman,Ramasubbamma Ramaiah et al.
Dasari Sahithi et al.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent anticancer agent capable of selectively triggering apoptosis in malignant cells while sparing normal tissues. Clinical translation of TRAIL is limited by rapid syst...
Prognostic Utility of Circulating Tumor DNA in Classical Hodgkin Lymphoma: A Systematic Review and Individual Participant Data Bayesian Meta-Analysis [0.03%]
经典霍奇金淋巴瘤中循环肿瘤DNA的预后价值：系统评价与个体患者数据Bayesian meta分析
Amirhossein Shahsavand,Shayan Forghani,Mohammadamin Kharaghani et al.
Amirhossein Shahsavand et al.
Over 20% of patients with Hodgkin lymphoma (HL) experience disease progression after initial treatment. We evaluated the prognostic utility of circulating tumor DNA (ctDNA) in HL patients. We systematically searched PubMed, Embase, the Coch...
KRAS Mutations Reshape the Immunosuppressive Tumor Microenvironment in Triple-Negative Breast Cancer: A Novel Perspective [0.03%]
KRAS突变从新视角重新定义了三阴性乳腺癌的免疫抑制型肿瘤微环境
Yuanhao Lv,Ziyin Zhao,Wenyu Di et al.
Yuanhao Lv et al.
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by poor prognosis and limited therapeutic options due to the lack of well-defined molecular targets. While conventional studies have primarily focused on tumor cell...
Cancer-Associated Thrombosis in the Era of Precision Oncology: Mechanisms, Challenges and Future Directions [0.03%]
精准肿瘤学时代癌症相关血栓的发生机制、挑战与未来方向
Chaonan He,Xianghao Dai,Dongyu Feng et al.
Chaonan He et al.
Cancer-associated thrombosis (CAT) is a common and life-threatening complication in cancer patients, leading to poor prognosis and reduced survival rate. The pathophysiology process of CAT is driven by a complex interplay of tumor-related p...
IMMUNOTHERAPY IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA: THE CURRENT STATUS AND FUTURE OUTLOOK [0.03%]
局部晚期头颈部鳞癌的免疫治疗：现状与未来展望
Bahadır Köylü,Fatih Selçukbiricik,Sercan Aksoy et al.
Bahadır Köylü et al.
Head and neck squamous cell carcinoma presents a significant global health burden, with the majority of cases diagnosed at a locally advanced stage requiring multimodal therapy. While the immune checkpoint inhibitors have transformed outcom...